Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Presents Preclinical Data on Beta-Thalassemia, Erythropoiesis Efforts

Premium

Alnylam Pharmaceuticals this week released new preclinical data from programs in beta-thalassemia and erythropoiesis — indications from which the company could select its newest pipeline candidate.

Alnylam, which presented the data at the American Society of Hematology annual meeting, said that it and collaborators showed that the systemic administration of a lipid nanoparticle-formulated siRNA targeting the gene transmembrane protease, serine 6, triggered an increase in hepcidin mRNA levels in mouse models of iron overload in beta-thalassemia.

As a result, the mice experienced significant decreases in serum iron concentration and transferrin saturation.

“Moreover, Tmprss6 silencing with a single dose of the RNAi therapeutic was associated with a dramatic normalization of multiple hematological parameters including hemoglobin, normalization of splenic iron levels and tissue histology, and reductions in splenomegaly,” Alnylam said. “These findings suggest that iron restriction via Tmprss6 silencing can correct the disease phenotype of beta-thalassemia intermedia in a pre-clinical model.”

Company researchers also reported that systemically delivered lipid nanoparticles loaded with siRNAs against liver-expressed egl-nine homolog prolyl hydroxlase genes could induce hepatic erythropoietin mRNA activation, which led to increased serum erythropoietin levels and stimulation of red blood cell production in animal models.

“Following a single dose, increases in serum EPO and hematocrit were durable for approximately two weeks and one month, respectively,” Alnylam said, adding that the treatment corrected anemia in both renal failure and inflammatory anemia disease models.

In a statement, Alnylam CMO Akshay Vaishnaw said that the company remains on track to announce a new drug candidate by year end.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.